Electrostatic Patch Effect in Cylindrical Geometry. III. Torques

We continue to study the effect of uneven voltage distribution on two close cylindrical conductors with parallel axes started in our papers [1] and [2], now to find the electrostatic torques. We calculate the electrostatic potential and energy to lowest order in the gap to cylinder radius ratio for an arbitrary relative rotation of the cylinders about their symmetry axis. By energy conservation, the axial torque, independent of the uniform voltage difference, is found as a derivative of the energy in the rotation angle. We also derive both the axial and slanting torques by the surface integration method: the torque vector is the integral over the cylinder surface of the cross product of the electrostatic force on a surface element and its position vector. The slanting torque consists of two parts: one coming from the interaction between the patch and the uniform voltages, and the other due to the patch interaction. General properties of the torques are described. A convenient model of a localized patch suggested in [2] is used to calculate the torques explicitly in terms of elementary functions. Based on this, we analyze in detail patch interaction for one pair of patches, namely, the torque dependence on the patch parameters (width and strength) and their mutual positions. The effect of the axial torque is then studied for the experimental conditions of the STEP mission.Comment: 28 pages, 6 Figures. Submitted to Classical Quantum Gravit

Thromboembolic events in patients treated with anti-angiogenic drugs

Induction of neo-angiogenesis is a fundamental step in many pathological conditions. The therapeutic value of inhibiting angiogenesis is an interesting area of research in oncology, with vascular endothelial growth factor (VEGF) being the most suitable anti-angiogenic target. In the last decade a number of anti-VEGF drugs have demonstrated, especially in combination with standard chemotherapy, clinical efficacy in the treatment of different solid tumor types. As data from clinical trials on anti-VEGF drugs are becoming available, it is increasingly recognized that VEGF, in addition to being a permeability, proliferation, and migration factor, is also a maintenance and protection factor for endothelial cells, being capable of regulating multiple biological functions, i.e. the production of vasoactive mediators and the expression of components of the thrombolytic and coagulation pathways. Consequently, the disturbance of vascular homeostasis by blocking VEGF may lead to endothelial dysfunction and adverse vascular effects, such as venous and arterial thromboembolic events. In preclinical models angiogenesis and the increased expression of VEGF has been associated to altered expression of proinflammatory genes. These genes may be regulated in a biphasic manner, and it is possible that anti-VEGF therapy may disrupt a negative feedback loop that leads to potential in situ thrombus formation. Accordingly, combination treatment with bevacizumab and chemotherapy, compared with chemotherapy alone, was recently associated with an increased risk of thromboembolism. The present review considers the biological mechanisms and clinical impact of thromboembolic complications during anti-angiogenic treatments in cancer patients

Platelet activation in type 2 diabetes mellitus

The abnormal metabolic state that accompanies diabetes renders arteries susceptible to atherosclerosis, being capable of altering the functional properties of multiple cell types, including endothelium and platelets. In particular, an altered platelet metabolism and changes in intraplatelet signaling pathways may contribute to the pathogenesis of atherothrombotic complications of diabetes. A variety of mechanisms may be responsible for enhanced platelet aggregation. Among them, hyperglycemia may represent a causal factor for in vivo platelet activation, and may be responsible for nonenzymatic glycation of platelet glycoproteins, causing changes in their structure and conformation, as well as alterations of membrane lipid dynamics. Furthermore, hyperglycemia-induced oxidative stress is responsible for enhanced peroxidation of arachidonic acid to form biologically active isoprostanes, which represents an important biochemical link between impaired glycemic control and persistent platelet activation. Finally, increased oxidative stress is responsible for activation of transcription factors and expression of redox-sensitive genes leading to a phenotypic switch of endothelium toward an adhesive, prothrombotic condition, initial platelet activation, adhesion and subsequent platelet aggregate formation. All this evidence is strengthened by the results of clinical trials documenting the beneficial effects of metabolic control on platelet function, and by the finding that aspirin treatment may even be more beneficial in diabetic than in high-risk non-diabetic patients. Attention to appropriate medical management of diabetic patients will have great impact on long-term outcome in this high-risk population. © 2004 International Society on Thrombosis and Haemostasis

Pion Number Fluctuations and Correlations in the Statistical System with Fixed Isospin

The statistical system of pions with zero total isospin is studied. The suppression effects for the average yields due to isospin conservation are the same for $\pi^0$, $\pi^+$ and $\pi^-$. However, a behavior of the corresponding particle number fluctuations are different. For neutral pions there is the enhancement of the fluctuations, whereas for charged pions the isospin conservation suppresses fluctuations. The correlations between the numbers of charged and neutral pions are observed for finite systems. This causes a maximum of the total pion number fluctuations for small systems. The thermodynamic limit values for the scaled variances of neutral and charged pions are calculated. The enhancements of the fluctuations due to Bose statistics are found and discussed

Particle Number Fluctuations in Statistical Model with Exact Charge Conservation Laws

Even though the first momenta i.e. the ensemble average quantities in canonical ensemble (CE) give the grand canonical (GC) results in large multiplicity limit, the fluctuations involving second moments do not respect this asymptotic behaviour. Instead, the asymptotics are strikingly different, giving a new handle in study of statistical particle number fluctuations in relativistic nuclear reactions. Here we study the analytical large volume asymptotics to general case of multispecies hadron gas carrying fixed baryon number, strangeness and electric charge. By means of Monte Carlo simulations we have also studied the general multiplicity probability distributions taking into account the decay chains of resonance states.Comment: 4 pages, 2 figures. The report of the talk given in Strangeness in Quark Matter 2004, Cape Town. Submitted to J. Phys. G: Nucl. Part. Phy

Non-steroidal anti-inflammatory drugs in cancer prevention and therapy

Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) can be regarded as an effective approach for cancer chemoprevention, as demonstrated by a bulk of clinical and experimental evidence. However, the clinical use of these drugs as chemopreventive agents is limited by many open questions about the optimal drug, dose, duration of therapy and knowledge about the mechanism(s) by which these drugs act. In particular, the recent data on cardiovascular toxicity of coxibs has posed some limitations on the use of NSAIDs for cancer chemoprevention in the general population. The situation is different in certain genetically susceptible subgroups, such as in individuals with genetic mutations associated with hereditary nonpolyposis colon cancer (HNPCC) or familiar adenomatous polyps (FAP) in whom lifetime risk increases up to 70-90% and in whom the benefit of a chemopreventive drug might justify its use even in the presence of adverse effects

Interleukin-2 inhalation therapy in renal cell cancer: a case report and review of the literature

Renal cell carcinoma (RCC) is the most common malignancy of the kidney. One third of RCC presents metastatic disease at the time of diagnosis, usually leading to a fatal outcome. Small response rates were seen with most cytotoxic agents including gemcitabine and vinorelbine, whereas systemic therapy with high doses of interleukin 2 (IL-2) has been shown to provide durable complete remissions. However, in consideration of its severe toxicity, IL-2 immunotherapy is restricted to selected patients. Aerosol IL-2 has been introduced as an alternative therapy in cancer patients. However, only very few data are available on its use in patients with pulmonary metastatic RCC. This paper briefly summarizes current clinical experience with the use of inhaled IL-2 therapy, either as a single therapy or in combination with other treatments. In addition, we report on a male patient with pulmonary metastasized RCC who achieved a durable complete response to combined gemcitabine/vinorelbine and interleukin-2 inhalation therapy

Non-steroidal anti-inflammatory drugs in cancer prevention and therapy

Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) can be regarded as an effective approach for cancer chemoprevention, as demonstrated by a bulk of clinical and experimental evidence. However, the clinical use of these drugs as chemopreventive agents is limited by many open questions about the optimal drug, dose, duration of therapy and knowledge about the mechanism(s) by which these drugs act. In particular, the recent data on cardiovascular toxicity of coxibs has posed some limitations on the use of NSAIDs for cancer chemoprevention in the general population. The situation is different in certain genetically susceptible subgroups, such as in individuals with genetic mutations associated with hereditary nonpolyposis colon cancer (HNPCC) or familiar adenomatous polyps (FAP) in whom lifetime risk increases up to 70-90% and in whom the benefit of a chemopreventive drug might justify its use even in the presence of adverse effects